This is the text extract for Annual Review 2002/03 - Highlights, browse documents here.

Annual Review -- Highlights of 2002-03

• Providing new or expanded access to 10 subsidised treatments, including those for chronic myeloid leukaemia, anaemia associated with kidney failure, breast cancer, heavy menstrual bleeding and osteoporosis. Containing community pharmaceutical expenditure growth by successfully negotiating savings worth approximately $50.3 million. Negotiated nationally -consistent supply contracts for 112 medicines used in DHB hospitals. Developing and implementing a process for assessing new pharmaceuticals for use in hospitals. Released and commenced implementation of the Maori Responsiveness Strategy. Running information campaigns such as the Wise Use of Antibiotics, Responsible Use of Inhaled Corticosteroids, and the regional pilots of the One Heart Many Lives campaign. Maori members appointed to PHARMAC bodies including the Consumer Advisory Committee (CAC), Pharmacology and Therapeutics Advisory Committee (PTAC) and the PHARMAC Board. Improvements to the administration of the Exceptional Circumstances scheme.

• • • • •

•

•

[ends]

For more information call (021) 863-342.